On assessing potential efficacy for vortioxetine in generalized anxiety disorder.
David S
DS
Baldwin
David J
DJ
Nutt
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D013440:Sulfides / Q000627:therapeutic use*; D016896:Treatment Outcome; D000078784:Vortioxetine
D014151:Anti-Anxiety Agents; D010879:Piperazines; D013440:Sulfides; D000078784:Vortioxetine